Serum Levels of Autoantibodies to Desmoglein 3 in Patients with Therapy-resistant Pemphigus Vulgaris Successfully Treated with Adjuvant Intravenous Immunoglobulins

Acta Dermato-Venereologica

Volumn 84, Issue 1, 2004, Pages 48-52

  Herzog, Susanne ^a   Schmidt, Enno ^a   Goebeler, Matthias ^a   Bröcker, Eva B ^a   Zillikens, Detlef ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Autoimmunity; Bullous disease; Desmosome

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DESMOGLEIN 3; DEXAMETHASONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ACNE; ADJUVANT THERAPY; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNITY; BLISTER; CASE REPORT; DEPRESSION; DESMOSOME; DIABETES MELLITUS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAIR LOSS; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOSUPPRESSIVE TREATMENT; OSTEOPOROSIS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; SIDE EFFECT; STRIA; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ADULT; AGED; AUTOANTIBODIES; CADHERINS; DESMOGLEIN 3; DRUG RESISTANCE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PEMPHIGUS;

EID: 0842264237     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550310005861     Document Type: Article

References (28)

1. Anhalt GJ, Diaz LA. Prospects for autoimmune diseases: research advances in pemphigus. JAMA 2001; 285: 652.
2. Fitzpatrick RE, Newcomer VD. The correlation of disease activity and antibody titres in pemphigus. Arch Dermatol 1980; 116: 285-290.
3. Ishiji K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S, et al. Characterization of autoantibodies in pemphigus using antigen specific enzyme-linked immunosorbent assay with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010-2017.
4. Lenz P, Amagai M, Volc-Platzer B, Stingl G, Kirnbauer R. Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool. Arch Dermatol 1999; 135: 143-148.
5. Lever WF, Talbott JH. Pemphigus: a clinical analysis and follow-up study of sixty-two patients. Arch Dermatol Syphilol 1942; 46: 348-351.
6. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. Arch Dermatol 1996; 132: 203-212.
7. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobin. Science 1998; 282: 490-493.
8. Dalakas M, Illa I, Dambrosia J, Soueidan S, Stein D, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993; 329: 1993.
9. Beckers RCY, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 289-293.
10. Wever S, Zillikens D, Bröcker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammunoglobulin as adjuvant therapy. Br J Dermatol 1996; 135: 862-863.
11. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865-874.
12. Jolles S, Hughes J, Rustin M. Therapeutic failure of high-dose intravenous immunoglobulins in pemphigus vulgaris. J Am Acad Dermatol 1999; 40: 499-500.
13. Kroiss M, Vogt T, Landthaler M, Stolz W. High-dose intravenous immune globulin is also effective in linear IgA disease. Br J Dermatol 2000; 142: 582.
14. Urcelay M, McQueen A, Douglas WS. Cicatricial pemphigoid treated with intravenous immunoglobulin. Br J Dermatol 1997; 137: 477-478.
15. Ahmed A, Colon J. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid. Arch Dermatol 2001; 137: 1181-1189.
16. Chan LS, Ahmed RA, Anhalt GJ, et al. The first international consensus on mucous membranes pemphigoid. Arch Dermatol 2000; 138: 370-378.
17. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80-86.
18. Volc-Platzer B. Immunglobulinbehandlung in der Dermatologie. Hautarzt 2001; 52: 264-277.
19. Fateh-Moghadam A, Besinger U, Wick M. High-dose immunoglobulin therapy in autoimmune diseases. Immun Infect 1984; 12: 129-133.
20. Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth JN, Melin M, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1994; 68: 459-475.
21. Jolles S. A review of high-dose intravenous immunoglobulin in the treatment of the autoimmune blistering disorders. Clin Exp Dermatol 2001; 26: 127-131.
22. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 1988; 119: 73-77.
23. Amagai M, Komai A, Hashimoto T, Shirakata Y, Hashimoto K, Yamada T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999; 140: 351-357.
24. Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermtol 1996; 135: 128-129.
25. Colonna L, Cianchini G, Frezzolini A, De Pita O, Di Lella G, Puddu P. Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy? Br J Dermatol 1998; 138: 1102-1103.
26. Engineer L, Bhol K, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000; 43: 1049-1057.
27. Enk AH, Knop J. Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceous with intravenous immunoglobulins. Hautarzt 1998; 49: 774-776.
28. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679-690.